Related Experiment Video
Updated: May 12, 2026
09:03
Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
Published on: August 25, 2019
ACMG statement on noninvasive prenatal screening for fetal aneuploidy
Anthony R Gregg1, S J Gross, R G Best
1Department of Obstetrics and Gynecology, University of Florida, Gainesville, FL, USA. greggar@ufl.edu
Summary
Noninvasive fetal aneuploidy screening using cell-free fetal DNA offers a new option for patients. Obstetric providers need to understand its benefits and risks for informed counseling and quality testing.
Area of Science:
- Genomics
- Molecular Biology
- Bioinformatics
Background:
- Next-generation sequencing enables noninvasive fetal genome assessment.
- Isolation of fetal DNA from maternal circulation is now feasible.
Framework:
- Noninvasive fetal aneuploidy screening utilizes cell-free fetal DNA (cfDNA).
- Proprietary bioinformatics tools are essential for accurate analysis.
Implementation:
- Obstetric care providers require education on cfDNA screening advantages and disadvantages.
- Efficient pretest and posttest counseling is crucial for patient care.
- Laboratories must maintain high standards for quality control and proficiency testing.
Implications:
- This technology represents a significant advancement in prenatal diagnostics.
- It paves the way for future applications like whole fetal genome/exome sequencing.
- Ensuring accurate test results and informed patient counseling is paramount.
